GLP1 is a natural hormone generated by specific cells that line the lower gut. It offers numerous health benefits, making the search for drugs that replicate its effects a "gold rush" in the pharmaceutical sector. Denmark's economy has soared due to Novo Nordisk's success with their weekly Semaglutide injection. However, several more affordable oral GLP1 mimicking drugs are currently in trials and are being closely monitored by savvy investors.
Among the various beneficial effects, GLP1 acts as a signal to cease eating and to slow down stomach emptying. Typically, most food is digested in the upper part of the gut, but when excess food reaches the lower part, it triggers the production of GLP1. Fiber is not easily digested, and short chain fatty acids produced from the fermentation of fiber strongly stimulate GLP1 production. In fact, fiber not only prompts GLP1 secretion but also increases the number of specialized cells that produce it. A more drastic method to boost GLP1 production is through gastric bypass surgery, which directs undigested food to the lower intestine. The increase in GLP1 is largely responsible for the remission of type 2 diabetes, which cannot be solely explained by energy restriction.
Besides boosting GLP1 production, SCFAs like butyrate serve as crucial intestinal nutrients and signaling molecules that engage with SCFA receptors found on the surface of various cell types in the body, including immune cells that control inflammation.
A High Fiber, Low Carb Diet is a better solution for diabetes than weekly GLP1 drug injections.
Comments